Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells

✍ Scribed by Jinsang Yoo; Yong J. Lee

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 712 KB
• Volume: 103
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.21389

✦ Synopsis

Abstract

Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is a promising cancer therapeutic agent because of its tumor selectivity. TRAIL is known to induce apoptosis in cancer cells but spare most normal cells. In the previous study [Yoo and Lee, 2007], we have reported that hyperthermia could enhance the cytotoxicity of TRAIL‐induced apoptosis. We observed in human colorectal cancer cell line CX‐1 that TRAIL‐induced apoptotic death and also that mild hyperthermia promoted TRAIL‐induced apoptotic death through caspase activation and cytochrome‐c release. Although its effects in vivo are not clear, hyperthermia has been used as an adjunctive therapy for cancer. Hyperthermia is often accompanied by chemotherapy to enhance its effect. In this study, CX‐1 colorectal adenocarcinoma cells were treated with TRAIL concurrently with hyperthermia and oxaliplatin or melphalan. To evaluate the cell death effects on tumor cells via hyperthermia and TRAIL and chemotherapeutic agents, FACS analysis, DNA fragmentation, and immunoblottings for PARP‐1 and several caspases and antiapoptotic proteins were performed. Activities of casapse‐8, caspase‐9, and caspase‐3 were also measured in hyperthermic condition. Interestingly, when analyzed with Western blot, we detected little change in the intracellular levels of proteins related to apoptosis. Clonogenic assay shows, however, that chemotherapeutic agents will trigger cancer cell death, either apoptotic or non‐apoptotic, more efficiently. We demonstrate here that CX‐1 cells exposed to 42°C and chemotherapeutic agents were sensitized and died by apoptotic and non‐apoptotic cell death even in low concentration (10 ng/ml) of TRAIL. J. Cell. Biochem. 103: 98–109, 2008. © 2007 Wiley‐Liss, Inc.